RefloDx, Inc. Secures $2M Seed Round to Accelerate SondeFlux™ Innovation in Smarter, Cost-Effective Healthcare

We are thrilled to announce that RefloDx, Inc., an innovative medical device startup spun out of the University of Utah, has successfully raised $2,000,000 in funding. This critical infusion of capital marks a significant milestone in our journey to bring cutting-edge healthcare solutions to market and reinforces our mission to provide better health through smarter science. At the heart of our innovation is our patented SondeFlux™ technology—a game changer in the realm of noninvasive diagnostic tools. SondeFlux™ utilizes ultrasound technology to detect and differentiate materials in the upper esophagus, enabling clinicians to accurately assess a patient’s risk of aspiration from extraesophageal reflux (EER). Its ability to quickly identify Laryngopharyngeal Reflux (LPR) across pediatric, adult, and geriatric patient populations revolutionizes the current diagnostic process by reducing the number of visits required and significantly cutting down the time to diagnosis. The funds raised will primarily be dedicated to advancing the market readiness of SondeFlux™, including expanded clinical trials, regulatory activities, and manufacturing scale-up to ensure that this innovative technology is accessible to healthcare providers nationwide. Additionally, the new capital will support strategic partnerships and outreach initiatives geared towards integrating SondeFlux™ into diverse clinical workflows, ultimately improving patient outcomes while reducing billions in unnecessary healthcare expenditures. As we move forward, RefloDx remains committed to disrupting the status quo in patient care, fostering smarter scientific solutions that not only enhance diagnostic accuracy but also translate into real-world savings and improved quality of life for patients around the globe.